首页> 外文期刊>AIDS >Abacavir induces loading of novel self-peptides into HLA-B*57: 01: An autoimmune model for HLA-associated drug hypersensitivity
【24h】

Abacavir induces loading of novel self-peptides into HLA-B*57: 01: An autoimmune model for HLA-associated drug hypersensitivity

机译:阿巴卡韦诱导HLA-B * 57上载新的自身肽:01:HLA相关药物超敏反应的自身免疫模型

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Abacavir drug hypersensitivity in HIV-treated patients is associated with HLA-B*57:01 expression. To understand the immunochemistry of abacavir drug reactions, we investigated the effects of abacavir on HLA-B*57:01 epitope-binding in vitro and the quality and quantity of self-peptides presented by HLA-B*57:01 from abacavir-treated cells. Design and Methods: An HLA-B*57:01-specific epitope-binding assay was developed to test for effects of abacavir, didanosine or flucloxacillin on self-peptide binding. To examine whether abacavir alters the peptide repertoire in HLA-B*57:01, a B-cell line secreting soluble human leucocyte antigen (sHLA) was cultured in the presence or absence of abacavir, peptides were eluted from purified human leucocyte antigen (HLA), and the peptide epitopes comparatively mapped by mass spectroscopy to identify drug-unique peptides. Results: Abacavir, but not didansosine or flucloxacillin, enhanced binding of the FITC-labeled self-peptide LF9 to HLA-B*57:01 in a dose-dependent manner. Endogenous peptides isolated from abacavir-treated HLA-B*57:01 B cells showed amino acid sequence differences compared with peptides from untreated cells. Novel drug-induced peptides lacked typical carboxyl (C) terminal amino acids characteristic of the HLA-B*57:01 peptide motif and instead contained predominantly isoleucine or leucine residues. Drug-induced peptides bind to soluble HLA-B*57:01 with high affinity that was not altered by abacavir addition. Conclusion: Our results support a model of drug-induced autoimmunity in which abacavir alters the quantity and quality of self-peptide loading into HLA-B*57:01. Drug-induced loading of novel self-peptides into HLA, possibly by abacavir either altering the binding cleft or modifying the peptide-loading complex, generates an array of neo-antigen peptides that drive polyclonal T-cell autoimmune responses and multiorgan systemic toxicity.
机译:背景:HIV治疗患者中的阿巴卡韦药物超敏性与HLA-B * 57:01表达相关。为了了解阿巴卡韦药物反应的免疫化学,我们调查了阿巴卡韦对体外HLA-B * 57:01表位结合的影响以及由阿巴卡韦治疗的HLA-B * 57:01呈现的自肽的质量和数量细胞。设计与方法:开发了HLA-B * 57:01特异性表位结合测定法,以测试阿巴卡韦,二羟肌苷或氟氯西林对自身肽结合的影响。为了检查abacavir是否会改变HLA-B * 57:01中的肽库,在有或没有abacavir的情况下培养分泌可溶性人白细胞抗原(sHLA)的B细胞系,从纯化的人白细胞抗原(HLA)洗脱肽),并通过质谱法比较绘制肽表位,以鉴定药物独特的肽。结果:阿巴卡韦(而非阿地卡索或氟氯西林)以剂量依赖的方式增强了FITC标记的自肽LF9与HLA-B * 57:01的结合。从阿巴卡韦处理的HLA-B * 57:01 B细胞中分离出的内源肽与未处理的细胞相比,显示出氨基酸序列差异。新型药物诱导的肽缺乏HLA-B * 57:01肽基序的典型羧基(C)末端氨基酸,而是主要包含异亮氨酸或亮氨酸残基。药物诱导的肽以高亲和力与可溶性HLA-B * 57:01结合,而阿巴卡韦的添加并没有改变这种亲和力。结论:我们的结果支持了药物诱导的自身免疫模型,其中阿巴卡韦改变了自身肽装载到HLA-B * 57:01中的数量和质量。药物诱导的新型自身肽可能通过阿巴卡韦(Acacavir)改变结合裂隙或修饰肽加载复合物而加载到HLA中,产生了一系列新抗原肽,这些新抗原肽驱动多克隆T细胞自身免疫反应和多器官系统毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号